Revvity, Inc. (PKI) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1159064,
    "name": "Revvity, Inc.",
    "stock_name": "Revvity, Inc.",
    "full_name": "Revvity, Inc.",
    "name_url": "stocks-analysis/revvity-inc",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "102.55",
    "chg": -0.71,
    "chgp": "-0.69%",
    "dir": -1,
    "prev_price": "103.26",
    "mcapval": "10,014.74",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US7140461093",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "602.5 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/revvity-inc-1159064-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Revvity, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-revvity-inc-overvalued-or-undervalued-3673408",
        "imagepath": "",
        "date": "2025-11-05 11:10:57",
        "description": "As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a shift towards overvaluation. The company appears to be overvalued, with a P/E ratio of 33, an EV to EBITDA of 15.29, and a PEG ratio of 3.05, which are all higher than the industry average. In comparison, The Cooper Cos., Inc. has a P/E of 34.28 and an EV to EBITDA of 14.70, while Align Technology, Inc. shows a more favorable P/E of 20.46 and an EV to EBITDA of 11.41.\n\nFurthermore, Revvity's stock has underperformed relative to the S&P 500, with a year-to-date return of -17.85% compared to the S&P 500's 16.30%, and a three-year return of -28.07% versus the S&P 500's 76.66%. This significant underperformance reinforces the notion that the stock is overvalued in its current state...."
      },
      {
        "title": "Is Revvity, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-revvity-inc-overvalued-or-undervalued-3670602",
        "imagepath": "",
        "date": "2025-11-04 11:16:55",
        "description": "As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a significant shift in its market perception. The company appears to be overvalued based on its current metrics, including a P/E ratio of 33, a Price to Book Value of 1.42, and an EV to EBITDA ratio of 15.29. In comparison, peers such as Hologic, Inc. have a fair valuation with a P/E ratio of 21.83, while The Cooper Companies, Inc. is also considered very expensive with a P/E of 34.28.\n\nThe stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -16.70% compared to the S&P 500's 16.30%, and a three-year return of -27.07% versus 76.66% for the index. This underperformance further supports the conclusion that Revvity, Inc. is currently overvalued in the market...."
      },
      {
        "title": "Is Revvity, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-revvity-inc-overvalued-or-undervalued-3666170",
        "imagepath": "",
        "date": "2025-11-03 11:16:21",
        "description": "As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its key financial metrics, including a P/E ratio of 33, an EV to EBITDA ratio of 15.29, and a PEG ratio of 3.05. In comparison, peers such as Hologic, Inc. and Align Technology, Inc. have more favorable valuations with P/E ratios of 21.83 and 20.46, respectively, suggesting that Revvity's stock is priced at a premium relative to its industry counterparts.\n\nAdditionally, Revvity has underperformed against the S&P 500, with a year-to-date return of -16.15% compared to the index's positive return of 16.30%. This underperformance, alongside its elevated valuation ratios, reinforces the conclusion that Revvity, Inc. is currently overvalued...."
      },
      {
        "title": "Is Revvity, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-revvity-inc-overvalued-or-undervalued-3664303",
        "imagepath": "",
        "date": "2025-11-02 11:09:23",
        "description": "As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a P/E ratio of 33, an EV to EBITDA of 15.29, and a PEG ratio of 3.05, all of which suggest that the stock price may not be justified by its earnings growth prospects. In comparison, The Cooper Cos., Inc. has a higher P/E of 34.28, while Align Technology, Inc. shows a much lower P/E of 20.46, highlighting the disparity in valuation among peers.\n\nRecent stock performance further reinforces this valuation concern, as Revvity, Inc. has underperformed against the S&P 500, with a year-to-date return of -16.15% compared to the index's 16.30%. This trend of negative returns over multiple periods, including a 1-year return of -21.08% versus the S&P 500's 19.89%, suggests that investor sentiment may be shifting away fr..."
      },
      {
        "title": "Is Revvity, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-revvity-inc-overvalued-or-undervalued-3637735",
        "imagepath": "",
        "date": "2025-10-21 12:08:01",
        "description": "As of 17 October 2025, the valuation grade for Revvity, Inc. has moved from fair to very expensive. The company is overvalued based on its current metrics, which include a P/E ratio of 33, an EV to EBITDA ratio of 15.29, and a PEG ratio of 3.05. In comparison, Hologic, Inc. has a fair valuation with a P/E ratio of 21.83, while The Cooper Companies, Inc. is considered expensive with a P/E ratio of 34.28.\n\nRevvity's recent stock performance has been notably poor, with a year-to-date return of -16.30%, significantly underperforming the S&P 500's return of 13.30% in the same period. This trend continues over longer periods, indicating that the stock is not only overvalued but also struggling in the market relative to broader benchmarks...."
      },
      {
        "title": "Revvity, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/revvity-inc-sees-valuation-grade-shift-from-fair-to-very-expensive-amid-decline-3640866",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/RevvityInc_valuationdot_3640866.png",
        "date": "2025-10-20 16:44:44",
        "description": "Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a valuation adjustment, with a current P/E ratio of 33. Its performance has been mixed, showing a year-to-date return of -16.30% and a decline of 21.53% over the past year, contrasting with the S&P 500's gains."
      },
      {
        "title": "Is Revvity, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-revvity-inc-overvalued-or-undervalued-3634610",
        "imagepath": "",
        "date": "2025-10-20 12:25:29",
        "description": "As of 17 October 2025, the valuation grade for Revvity, Inc. has moved from fair to very expensive, indicating a significant concern regarding its current pricing relative to its financial metrics. The company is considered overvalued, especially given its P/E ratio of 33, which is notably higher than peers such as Hologic, Inc. with a P/E of 21.83 and The Cooper Companies at 34.28. Additionally, Revvity's EV to EBITDA stands at 15.29, which is also above the industry average, further supporting the overvaluation stance.\n\nIn comparison to its peers, Revvity's PEG ratio of 3.05 suggests that its growth is not justifying its current price, as Hologic's PEG is significantly lower at 2.60. The company's return on equity (ROE) of 4.30% and return on capital employed (ROCE) of 4.39% are relatively low, indicating inefficiencies in generating returns from its capital. Furthermore, while Revvity has outperformed th..."
      },
      {
        "title": "Is Revvity, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-revvity-inc-overvalued-or-undervalued-3632144",
        "imagepath": "",
        "date": "2025-10-19 12:03:02",
        "description": "As of 17 October 2025, the valuation grade for Revvity, Inc. moved from fair to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 33, an EV to EBITDA of 15.29, and a PEG ratio of 3.05. In comparison, Hologic, Inc. has a fair valuation with a P/E of 21.83, while The Cooper Companies, Inc. is considered expensive with a P/E of 34.28, highlighting that Revvity's valuation is on the higher end relative to its peers.\n\nRecent stock performance shows that Revvity has underperformed compared to the S&P 500, with a year-to-date return of -16.30% versus the S&P 500's 13.30%. This trend continues over longer periods, with a 5-year return of -24.67% compared to the S&P 500's 91.29%, reinforcing the notion that Revvity, Inc. is currently overvalued...."
      },
      {
        "title": "Revvity, Inc. Experiences Evaluation Revision Amid Mixed Market Signals and Performance Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/revvity-inc-technical-trend-shifts-from-bearish-to-mildly-bearish-amid-stock-volatility-3601144",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/RevvityInc_technicaldot_3601144.png",
        "date": "2025-10-07 20:10:13",
        "description": "Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has seen its stock price decline recently amid a challenging year, marked by a 24.67% drop. Technical indicators present mixed signals, reflecting a complex market environment as Revvity's performance diverges significantly from the S&P 500."
      }
    ],
    "total": 19,
    "sid": "1159064",
    "stock_news_url": "https://www.marketsmojo.com/news/revvity-inc-1159064"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Revvity, Inc. overvalued or undervalued?

2025-11-05 11:10:57

As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a shift towards overvaluation. The company appears to be overvalued, with a P/E ratio of 33, an EV to EBITDA of 15.29, and a PEG ratio of 3.05, which are all higher than the industry average. In comparison, The Cooper Cos., Inc. has a P/E of 34.28 and an EV to EBITDA of 14.70, while Align Technology, Inc. shows a more favorable P/E of 20.46 and an EV to EBITDA of 11.41. Furthermore, Revvity's stock has underperformed relative to the S&P 500, with a year-to-date return of -17.85% compared to the S&P 500's 16.30%, and a three-year return of -28.07% versus the S&P 500's 76.66%. This significant underperformance reinforces the notion that the stock is overvalued in its current state....

Is Revvity, Inc. overvalued or undervalued?

2025-11-04 11:16:55

As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a significant shift in its market perception. The company appears to be overvalued based on its current metrics, including a P/E ratio of 33, a Price to Book Value of 1.42, and an EV to EBITDA ratio of 15.29. In comparison, peers such as Hologic, Inc. have a fair valuation with a P/E ratio of 21.83, while The Cooper Companies, Inc. is also considered very expensive with a P/E of 34.28. The stock has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -16.70% compared to the S&P 500's 16.30%, and a three-year return of -27.07% versus 76.66% for the index. This underperformance further supports the conclusion that Revvity, Inc. is currently overvalued in the market....

Is Revvity, Inc. overvalued or undervalued?

2025-11-03 11:16:21

As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its key financial metrics, including a P/E ratio of 33, an EV to EBITDA ratio of 15.29, and a PEG ratio of 3.05. In comparison, peers such as Hologic, Inc. and Align Technology, Inc. have more favorable valuations with P/E ratios of 21.83 and 20.46, respectively, suggesting that Revvity's stock is priced at a premium relative to its industry counterparts. Additionally, Revvity has underperformed against the S&P 500, with a year-to-date return of -16.15% compared to the index's positive return of 16.30%. This underperformance, alongside its elevated valuation ratios, reinforces the conclusion that Revvity, Inc. is currently overvalued....

Is Revvity, Inc. overvalued or undervalued?

2025-11-02 11:09:23

As of 31 October 2025, the valuation grade for Revvity, Inc. has moved from attractive to very expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a P/E ratio of 33, an EV to EBITDA of 15.29, and a PEG ratio of 3.05, all of which suggest that the stock price may not be justified by its earnings growth prospects. In comparison, The Cooper Cos., Inc. has a higher P/E of 34.28, while Align Technology, Inc. shows a much lower P/E of 20.46, highlighting the disparity in valuation among peers. Recent stock performance further reinforces this valuation concern, as Revvity, Inc. has underperformed against the S&P 500, with a year-to-date return of -16.15% compared to the index's 16.30%. This trend of negative returns over multiple periods, including a 1-year return of -21.08% versus the S&P 500's 19.89%, suggests that investor sentiment may be shifting away fr...

Is Revvity, Inc. overvalued or undervalued?

2025-10-21 12:08:01

As of 17 October 2025, the valuation grade for Revvity, Inc. has moved from fair to very expensive. The company is overvalued based on its current metrics, which include a P/E ratio of 33, an EV to EBITDA ratio of 15.29, and a PEG ratio of 3.05. In comparison, Hologic, Inc. has a fair valuation with a P/E ratio of 21.83, while The Cooper Companies, Inc. is considered expensive with a P/E ratio of 34.28. Revvity's recent stock performance has been notably poor, with a year-to-date return of -16.30%, significantly underperforming the S&P 500's return of 13.30% in the same period. This trend continues over longer periods, indicating that the stock is not only overvalued but also struggling in the market relative to broader benchmarks....

Revvity, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape

2025-10-20 16:44:44

Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a valuation adjustment, with a current P/E ratio of 33. Its performance has been mixed, showing a year-to-date return of -16.30% and a decline of 21.53% over the past year, contrasting with the S&P 500's gains.

Is Revvity, Inc. overvalued or undervalued?

2025-10-20 12:25:29

As of 17 October 2025, the valuation grade for Revvity, Inc. has moved from fair to very expensive, indicating a significant concern regarding its current pricing relative to its financial metrics. The company is considered overvalued, especially given its P/E ratio of 33, which is notably higher than peers such as Hologic, Inc. with a P/E of 21.83 and The Cooper Companies at 34.28. Additionally, Revvity's EV to EBITDA stands at 15.29, which is also above the industry average, further supporting the overvaluation stance. In comparison to its peers, Revvity's PEG ratio of 3.05 suggests that its growth is not justifying its current price, as Hologic's PEG is significantly lower at 2.60. The company's return on equity (ROE) of 4.30% and return on capital employed (ROCE) of 4.39% are relatively low, indicating inefficiencies in generating returns from its capital. Furthermore, while Revvity has outperformed th...

Is Revvity, Inc. overvalued or undervalued?

2025-10-19 12:03:02

As of 17 October 2025, the valuation grade for Revvity, Inc. moved from fair to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 33, an EV to EBITDA of 15.29, and a PEG ratio of 3.05. In comparison, Hologic, Inc. has a fair valuation with a P/E of 21.83, while The Cooper Companies, Inc. is considered expensive with a P/E of 34.28, highlighting that Revvity's valuation is on the higher end relative to its peers. Recent stock performance shows that Revvity has underperformed compared to the S&P 500, with a year-to-date return of -16.30% versus the S&P 500's 13.30%. This trend continues over longer periods, with a 5-year return of -24.67% compared to the S&P 500's 91.29%, reinforcing the notion that Revvity, Inc. is currently overvalued....

Revvity, Inc. Experiences Evaluation Revision Amid Mixed Market Signals and Performance Challenges

2025-10-07 20:10:13

Revvity, Inc., a small-cap company in the Pharmaceuticals & Biotechnology sector, has seen its stock price decline recently amid a challenging year, marked by a 24.67% drop. Technical indicators present mixed signals, reflecting a complex market environment as Revvity's performance diverges significantly from the S&P 500.

View All News